- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT00130247
Tuberculosis Treatment Shortening Trial
A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 3. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brazília, 29040-091
- Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center
-
-
-
-
National Capital Region
-
Makati, National Capital Region, Fülöp-szigetek, 1229
- Makati Medical Center
-
-
-
-
-
Kampala, Uganda, 99999
- Mulago Hospital Complex
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
-Adults, male or female, aged 18-60. -Newly diagnosed initial episodes of pulmonary tuberculosis. Sputum smear-positive and -negative patients are eligible for enrollment. The diagnosis of tuberculosis must be confirmed by culture. Acid fast bacteria (AFB) smear positive patients found later not to have tuberculosis (TB) (i.e. those with non-tuberculous mycobacterial disease) and those without culture confirmation [at least one culture on solid media growing > 10 colonies of Mycobacterium tuberculosis (MTB) or a positive BACTEC or Mycobacteria growth indicator tube (MGIT) enriched liquid culture growing MTB] will be removed from the study. -Chest X-ray and clinical findings consistent with tuberculosis. -Hemoglobin greater than or equal to 8 gm/dL (greater than or equal to 5.0 mmol/L). -Serum creatinine < 2 mg/dL (< 177 micro mol/L). -Serum aspartate aminotransferase (AST) < 1.5 times the upper limit of normal for the testing laboratory, and serum total bilirubin < 1.3 mg/dL (22.2 micro mol/L). -Random serum glucose less than or equal to 150 mg/dl (8.3 mmol/L). -Ambulatory. -Willing to provide informed consent for study participation, provide required specimens for examination, and to undergo and receive results of human immunodeficiency virus (HIV) testing. -Willing to receive supervised anti-TB treatment. -Completion of the required 112 doses of chemotherapy within 18 weeks of starting treatment.
Exclusion Criteria:
-Human immunodeficiency virus (HIV)-infected. -History of prior tuberculosis or history of previous tuberculosis treatment. -Pregnant or breastfeeding. -Cavitary tuberculosis on initial chest X-ray (taken within 14 days of study entry). -Exposure to person(s) with known drug resistant tuberculosis. -Patients receiving chronic steroids or other immunosuppressive medications. -Extra-pulmonary tuberculosis. -Patients with drug resistant tuberculosis (resistance to isoniazid (INH), rifampicin, pyrazinamide or ethambutol). -Professional sex worker, alcoholic and/or intravenous (IV) drug abuser. -Silicosis or other serious chronic medical problems including diabetes mellitus or chronic renal failure. Final determination of eligibility will be made after review of drug susceptibility testing results on an initial sputum isolate and results of all sputum cultures. Pregnant patients may not be enrolled in the study. Patients in the 4 month arm who become pregnant during months 5 and 6 of study participation will be dropped from the study and receive an additional 2 months of treatment with INH and rifampicin.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: 2EHRZ/2HR arm
Daily treatment with isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.
|
Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
|
Aktív összehasonlító: 2EHRZ/4HR arm
Daily treatment with Isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.
|
Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat
Időkeret: 30 months
|
Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses.
A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment.
|
30 months
|
Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-TB Treatment - Per-protocol
Időkeret: 30 months
|
Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses.
A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment.
|
30 months
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Intention to Treat
Időkeret: 2 years
|
A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity.
A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment.
Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence.
|
2 years
|
Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Per Protocol
Időkeret: 2 years
|
A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity.
A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment.
Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence.
|
2 years
|
Relapses at 1 and 2 Years
Időkeret: 1 and 2 years after successful completion of initial anti-TB treatment
|
1 and 2 years after successful completion of initial anti-TB treatment
|
|
Acquired Drug Resistance in Patients Who Relapsed
Időkeret: 2 years
|
2 years
|
|
Immunologic: Changes in Cytokine Levels in Mycobacterium Tubercolosis (MTB) Antigen-stimulated Whole Blood Culture Supernatants - Results Are Pending
Időkeret: After 2 and 6 months of anti-TB treatment and upon relapse
|
After 2 and 6 months of anti-TB treatment and upon relapse
|
|
Immunologic: Store Peripheral Blood Mononuclear Cells (PBMC) - Results Are Pending
Időkeret: Pre-treatment and serum pre-treatment after 2 and 6 months of anti-TB treatment, and at the time of relapse for future immunologic analysis
|
Pre-treatment and serum pre-treatment after 2 and 6 months of anti-TB treatment, and at the time of relapse for future immunologic analysis
|
|
Immunologic: Changes in Sputum Cytokine Levels - Results Are Pending
Időkeret: After 1 and 2 months of anti-TB treatment
|
After 1 and 2 months of anti-TB treatment
|
|
Microbiologic: Changes in Sputum Mycobacterial mRNA - Results Are Pending
Időkeret: At 1 and 2 months of anti-TB treatment, and upon relapse
|
At 1 and 2 months of anti-TB treatment, and upon relapse
|
|
Microbiologic: Time After Inoculation Until Culture Positive in BACTEC 460 or MGIT 960 Enriched Liquid Media After 2 Months in Treatment - Results Are Pending
Időkeret: Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 24, and 30
|
Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 24, and 30
|
Együttműködők és nyomozók
Publikációk és hasznos linkek
Általános kiadványok
- Johnson JL, Thiel BA. Time until relapse in tuberculosis treatment trials: implication for phase 3 trial design. Am J Respir Crit Care Med. 2012 Sep 1;186(5):464. doi: 10.1164/ajrccm.186.5.464. No abstract available.
- Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, Maciel EL, do Valle Dettoni V, Horter L, Boom WH, Johnson JL, Eisenach KD. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol. 2007 Dec;45(12):4064-6. doi: 10.1128/JCM.01780-07. Epub 2007 Oct 10.
- Bark CM, Dietze R, Okwera A, Quelapio MI, Thiel BA, Johnson JL. Clinical symptoms and microbiological outcomes in tuberculosis treatment trials. Tuberculosis (Edinb). 2011 Nov;91(6):601-4. doi: 10.1016/j.tube.2011.05.007. Epub 2011 Aug 2.
- Colangeli R, Jedrey H, Kim S, Connell R, Ma S, Chippada Venkata UD, Chakravorty S, Gupta A, Sizemore EE, Diem L, Sherman DR, Okwera A, Dietze R, Boom WH, Johnson JL, Mac Kenzie WR, Alland D; DMID 01-009/Tuberculosis Trials Consortium Study 22 Teams. Bacterial Factors That Predict Relapse after Tuberculosis Therapy. N Engl J Med. 2018 Aug 30;379(9):823-833. doi: 10.1056/NEJMoa1715849.
- Bark CM, Thiel BA, Johnson JL. Pretreatment time to detection of Mycobacterium tuberculosis in liquid culture is associated with relapse after therapy. J Clin Microbiol. 2012 Feb;50(2):538. doi: 10.1128/JCM.06193-11. Epub 2011 Nov 23. No abstract available.
- Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009 Sep 15;180(6):558-63. doi: 10.1164/rccm.200904-0536OC. Epub 2009 Jun 19.
- Maciel EL, Brioschi AP, Peres RL, Guidoni LM, Ribeiro FK, Hadad DJ, Vinhas SA, Zandonade E, Palaci M, Dietze R, Johnson JL. Smoking and 2-month culture conversion during anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2013 Feb;17(2):225-8. doi: 10.5588/ijtld.12.0426.
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Fertőzések
- Bakteriális fertőzések
- Bakteriális fertőzések és mikózisok
- Gram-pozitív bakteriális fertőzések
- Actinomycetales fertőzések
- Mycobacterium fertőzések
- Tuberkulózis
- A farmakológiai hatás molekuláris mechanizmusai
- Fertőzésgátló szerek
- Nukleinsav szintézis gátlók
- Enzim gátlók
- Antimetabolitok
- Hipolipidemiás szerek
- Lipidszabályozó szerek
- Antibakteriális szerek
- Leprosztatikus szerek
- Citokróm P-450 enziminduktorok
- Citokróm P-450 CYP3A induktorok
- Antituberkuláris szerek
- Antibiotikumok, tuberkulózis elleni szerek
- Citokróm P-450 CYP2B6 induktorok
- Citokróm P-450 CYP2C8 induktorok
- Citokróm P-450 CYP2C19 induktorok
- Citokróm P-450 CYP2C9 induktorok
- Zsírsav szintézis gátlók
- Rifampin
- Izoniazid
- Pirazinamid
- Etambutol
Egyéb vizsgálati azonosító számok
- 01-009
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
az Egyesült Államokban gyártott és onnan exportált termék
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Tuberkulózis
-
COPD FoundationToborzásNem CF Bronchiectasis | Non-tuberculosis Mycobacteria (NTM)Egyesült Államok
-
University Children's Hospital BaselUniversity Hospital, Geneva; University Hospital Inselspital, Berne; Kantonsspital... és más munkatársakToborzásTuberkulózis | Mycobacterium tuberculosisSvájc
-
National Institute of Allergy and Infectious Diseases...BefejezveMycobacterium tuberculosisBrazília
-
The University of Texas Health Science Center,...National Institute of Allergy and Infectious Diseases (NIAID)BefejezveMycobacterium tuberculosisEgyesült Államok, Colombia, Mexikó
-
National Institute of Allergy and Infectious Diseases...Befejezve
-
Boston UniversityUniversity of Florida; WestatVisszavontTuberculosis Multi Drug Resistant Active
-
Johns Hopkins UniversityMegszűntMycobacterium tuberculosisEgyesült Államok
-
National Institute of Allergy and Infectious Diseases...Befejezve
-
François SpertiniUniversity of OxfordBefejezveTuberkulózis | Mycobacterium Tuberculosis, elleni védelemSvájc
-
Region SkaneToborzásLappangó tuberkulózis | Mycobacterium tuberculosis | Tartós fertőzésSvédország
Klinikai vizsgálatok a Ethambutol
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the Witswatersrand és más munkatársakAktív, nem toborzóTuberkulózis | Több gyógyszerrezisztens tuberkulózis | Rifampicin rezisztens tuberkulózis | Kifejezetten gyógyszerrezisztens tuberkulózis | XDR-TB előttDél-Afrika
-
Vanderbilt UniversityBefejezve